- cafead   Mar 03, 2022 at 10:32: AM
via Finch Therapeutics' phase 3 trial for a Clostridioides difficile med has been placed on clinical hold by the FDA as the agency requests more information on how the biotech screens the donor-derived microbiome therapy for the virus that causes COVID-19.
article source
article source